Intellia Therapeutics’ lonvo-z makes use of CRISPR to inactivate a gene within the liver to cut back ranges of a protein key to the swelling assaults from the uncommon illness hereditary angioedema. Intellia has filed a regulatory submission for this genetic medication, which may develop into the primary in vivo gene-editing remedy to land FDA approval.
The publish Intellia’s Knowledge Reveal Tees Up FDA Submitting for CRISPR-Based mostly In Vivo Gene-Modifying Med appeared first on MedCity Information.
